Monoclonal antibodies in Pediatrics: Use in prevention and treatment

Allergologia et Immunopathologia

Volumn 35, Issue 4, 2007, Pages 145-150

  Martin Mateos, M A ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Allergic diseases; Anti IgE MAbs; Autoimmune diseases; Humanized MAbs; Hybridomas; Monoclonal antibodies (MAbs); Murine MAbs; Neoplasms; RSV prophylaxis; Severe asthma; Transplant rejection

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; ECULIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR GAMMA; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BRONCHIOLITIS; CHRONIC ARTHRITIS; CORONARY ARTERY DISEASE; CROHN DISEASE; DRUG INDUCED HEADACHE; GRAFT REJECTION; HUMAN; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; URTICARIA; UVEITIS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ASTHMA; AUTOIMMUNE DISEASES; BRONCHIOLITIS; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; HUMANS; HYPERSENSITIVITY; INFANT; INFANT, NEWBORN; NEOPLASMS; PEDIATRICS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 34548762411     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13108225     Document Type: Article

References (16)

1. Mikuls TR, Moreland LV. Monoclonal antibodies and soluble proteins receptors. En: Rich R.E: Clinical Immunology. Ed. Mosby. London, 2003.
2. Rosemberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001:411:380-384.
3. Kreitman R.J. Immunotoxins in cancer therapy. Current Opinion Immunol. 1999;11:570-578.
4. Cristillo AD, Bierner BE. Immunophilins and immunophilinbinding agents. En Rich R.E: Clinical Immunology. Ed. Mosby. London, 2003.
5. Giasanti F, Barberá ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab in the treatment of refractary posterior uveitis with retinal neovascularization in Behçet Syndrome" Eur J Ophthalmology 2004;14:445-8.
6. Richars J.C. Tay-Kearney M.L., Murray K. Manners P. A prospective trial of Infliximab therapy for refractory uveitis. Arch Ophthalmol.2005;33:461-8.
7. Targan SR, Hanauer SB, van Deventer SJ, Mayer Ll, Present DH, Braakman J, et al. A short-terme study of chimeric monoclonal antibody CA2 to tumor necrosis factor alfa, for Crohn's disease. N Engl J Med.1997;337:1029-33.
8. Fabry IV, Fleming HE, Wong HH. The effect of an anti IgE monoclonal antibody on the early and late face, response to allergens inhalation in asthmatic subjects. Am J. Res. Crit Care Med. 1997;155:1828-34.
9. Fahy J.V., Cockcroft DW, Boulet, LP, Wong HH, Deschesnes F, Davis EE, et al. Effect of aerosolized anti IgE (E25) on airway responses to inhaled allergens in asthmatic subjects. Am J Resp Crit Care Med. 1999;160:1023-1027.
10. Boulet LP, Chapman KR, Cote J, Kaira S, Bhagat R, Swystun VA, et al. Inhibitory effects of an anti IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Resp. Crit. Care. Med. 1997;155:1835-1840.
11. Babu KS, Arshad SH, Holgate ST. Anti-IgE treatment: an update. Allergy. 2001;56:1121-8
12. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecok S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergy asthma and persistent allergy rhinitis: SOLAR. Allergy. 2004;59:709-17
13. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy, 2005;60:693-6
14. Toledo F., Martínez R., Negro JM, Ramírez M, Mérida C. Anti IgE (omalizumab) en el tratamiento de la rinitis alérgica. Allergol Inmunol Clin. 2004;19:133-139.
15. Figueras J, Quero J y Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Pediatr. 2005;63:357-362.
16. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous cornary revascularization. J Am Coll Cardiol. 1997;30:149-56